Scientific Opinion on the Regulatory Status of 1,3-Dimethylamylamine (DMAA)
Published: 2012-11-26
Page: 93-100
Issue: 2012 - Volume 2 [Issue 4]
Bastiaan J. Venhuis *
RIVM - National Institute for Public Health and the Environment, P.O. Box 1, NL-3720 BA Bilthoven, The Netherlands.
Dries de Kaste
RIVM - National Institute for Public Health and the Environment, P.O. Box 1, NL-3720 BA Bilthoven, The Netherlands.
*Author to whom correspondence should be addressed.
Abstract
1,3-Dimethylamylamine (DMAA) is a pressor amine often found in food supplements for athletes at dosages of 25-65 mg. Historically, the compound has been used as a nasal decongestant but its oral application is largely unstudied leaving the regulatory status of such food supplements as unlicensed medicines undetermined. We therefore reviewed the literature on DMAA and similar amines in order to deduce an effective oral dosage. Based on our findings we conclude that oral preparations with >4 mg DMAA per dose unit should be considered as effective as a bronchodilator. Food supplements that exceed that limit are in fact subject to the Medicines Act and require licensing. Dosages higher than 100-200 mg are expected to cause serious adverse events.
Keywords: 1,3-Dimethylamylamine (DMAA), geranamine, regulatory status, food supplements, oral efficacy